|
|
Vaccine Detail
|
Autologous Oxidized Ovarian Tumor Cell Lysate Vaccine |
| Vaccine Information |
- Vaccine Name: Autologous Oxidized Ovarian Tumor Cell Lysate Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Live, attenuated vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Immunization Route: Intradermal injection (i.d.)
- Description: Cyclophosphamide/Fludarabine Lymphodepletion and an immunomodulatory combination of Interferon-alpha Bevacizumab and Aspirin followed by adoptive transfer of vaccine-primed ex vivo CD3/CD28-costimulated peripheral blood autologous T cells and vaccination with whole tumor vaccine administered intradermally in combination with Bevacizumab in patients with recurrent ovarian cancer fallopian tube or primary peritoneal cancer may help treat their tumors. Patients will receive 5-10 million cells intradermally. (NCT01312376)
|
| Host Response |
|
|
| References |
NCT01312376: Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer [https://clinicaltrials.gov/study/NCT01312376]
|
|
